We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
From May 2019 to May 2024
By Josh Beckerman
Pfizer Inc. shares rose 1.6% to $38.15 after hours, while BioNTech SE American depositary shares increased nearly 5% to $90.65 as the companies selected a coronavirus vaccine candidate to advance into a Phase 2/3 study.
The companies, which have studied multiple BNT162 RNA vaccine candidates, will advance BNT162b2 at a 30 ug dose level in a two-dose regimen.
Last week, the companies said the U.S. government agreed to pay $1.95 billion upon receiving the first 100 million doses of a vaccine in the BNT162 program.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
July 27, 2020 18:04 ET (22:04 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
